2012 Expert Reviews Ltd. AML: Acute myeloid leukemia; APL: Acute promyelocytic leukemia ... now have one or more discernable recurrent genetic mutations. Risk-adapted therapy has allowed for ...
In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.
to restore both transcriptional activity and RA-induced differentiation in RA-resistant acute promyelocytic leukemia (APL) cells. To target the MEK/ERK pathway, we identified glycogen synthase ...
Acute promyelocytic ... secondary mutations may be involved, and that integration site effects may also contribute to the disease phenotype. To better understand the role of leukemia oncogenes ...
Hosted on MSN1mon
How Leukemia Is Treated
Medically reviewed by Douglas A. Nelson, MD The treatment for leukemia depends on many factors, including the type, subtype, and stage of the disease, and a person’s age and general health ...